Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Additional thoughts on the ATM

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jul 25, 2021 5:06pm

86 Views

Post# 33602387

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Additional thoughts on the ATM

Now, we may want to consider that another shoe will drop realtively quickly that will help make sense of the late Friday PR with no explanation.

Also, did anyone else recieve the PR in their e-mail? Unlike other PR's, I did not get an e-mail for this one. Do they only e-mail out certain PR's? If so, that is a policy that needs to change.

Scioto1 wrote:
I agree scarlet. Not 5 months after a financial move without sound communication to shareholders, and all the turmoil that created, we get this release, end of the week with with no meaningful communication.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects